Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL154190 | 1.00 | CA1 (0.36) | CA1CA2CA4KMT2AEPHX1 | |
| SCHEMBL10578965 | 0.97 | — | — | |
| SCHEMBL276136 | 0.89 | — | — | |
| SCHEMBL4453317 | 0.89 | — | — | |
| SCHEMBL25217276 | 0.89 | — | — | |
| SCHEMBL25223861 | 0.89 | — | — | |
| SCHEMBL303875 | 0.77 | — | — | |
| SCHEMBL10582604 | 0.74 | CA1 (0.31) | CA1CA2CA4 | |
| SCHEMBL15121454 | 0.72 | — | — | |
| SCHEMBL864234 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023147312-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | EVVIA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2020123250-A1 | CANNABINOID DERIVATIVES AND METHODS FOR THEIR PREPARATION | HEANEY JOHN (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200179330-A1 | CANNABINOID DERIVATIVES AND METHODS FOR THEIR PREPARATION | HEANEY JOHN (US) | 2020-06-11 | — | — | US | disclosed |
| US-20150150819-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2015-06-04 | — | — | US | disclosed |
| US-20150126554-A1 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION | 2015-05-07 | — | — | US | disclosed |
| US-8946262-B2 | Methods of preventing and treating gastrointestinal dysfunction | ADOLOR CORPORATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-8895560-B2 | Opioid antagonists | ADOLOR CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140303211-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2014-10-09 | — | — | US | disclosed |
| US-20140186951-A1 | NOVEL OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140057947-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2005023799-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
| US-6852713-B2 | Lactam derivatives and methods of their use | ADOLOR CORPORATION (US) | 2005-02-08 | — | — | US | disclosed |
| WO-2005004796-A2 | SULFONYLAMINO PHENYLACETAMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20040254218-A1 | Substituted piperidine compounds and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2004-12-16 | — | — | US | disclosed |
| US-20040254156-A1 | Sulfonylamino phenylacetamide derivatives and methods of their use | CALIXA THERAPEUTICS, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004093796-A2 | LACTAM DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040209857-A1 | Lactam derivatives and methods of their use | ADOLOR CORPORATION | 2004-10-21 | — | — | US | disclosed |
| WO-2004082623-A2 | SUBSTITUTED PIPERIDINE COMPOUNDS | ADOLOR CORPORATION (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040186135-A1 | Substituted piperidine compounds | CUBIST PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057947-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | OPRK1, OPRL1, OPRM1 | CA1 3262/4885CA2 3253/4885CA4 3931/4885 |
| US-20040254218-A1 | Substituted piperidine compounds and methods of their use | OPRM1, OPRK1, OPRD1 | CA1 4527/4885CA2 3989/4885CA4 4275/4885 |
| US-20040186135-A1 | Substituted piperidine compounds | OPRK1, OPRD1, OPRM1 | CA1 4687/4885CA2 4304/4885CA4 4536/4885 |
| US-20040254156-A1 | Sulfonylamino phenylacetamide derivatives and methods of their use | CYP2E1, CYP2D6, CYP3A43 | CA1 2538/4885CA2 1540/4885CA4 2832/4885 |
| US-20150126554-A1 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | VIP, FABP2, SI | CA1 1427/4885CA2 2030/4885CA4 2340/4885 |
| US-20140303211-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | OPRK1, OPRL1, OPRM1 | CA1 3262/4885CA2 3253/4885CA4 3931/4885 |
| US-20150150819-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | OPRK1, OPRM1, OPRD1 | CA1 4326/4885CA2 4561/4885CA4 4573/4885 |
| US-20040209857-A1 | Lactam derivatives and methods of their use | MRPL21, SI, PEPD | CA1 1801/4885CA2 3874/4885CA4 2495/4885 |
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1 | CA1 500/4885CA2 636/4885CA4 465/4885 |
| US-20200179330-A1 | CANNABINOID DERIVATIVES AND METHODS FOR THEIR PREPARATION | CNR2, CNR1, GPR119 | CA1 3507/4885CA2 2473/4885CA4 3219/4885 |
| US-20140186951-A1 | NOVEL OPIOID ANTAGONISTS | OPRK1, OPRM1, OPRL1 | CA1 3819/4885CA2 3039/4885CA4 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.